Skip to main content

Wockhardt Reports Q2 Revenue of ₹969 Crore, Up From ₹782 Crore YoY

Wockhardt reported Q2 revenue of ₹969 cr, marking top-line expansion over ₹782 cr in the prior-year period (derived: ₹969 cr vs ₹782 cr, ≈23.91% growth).

Author Image
Sahi Markets
Published: 2 Nov 2026, 05:03 PM IST (1 hour ago)
Last Updated: 2 Nov 2026, 05:03 PM IST (1 hour ago)
1 min read
Reviewed by Arpit Seth

Market snapshot: Wockhardt Limited recorded Q2 revenue of ₹969 cr compared to ₹782 cr in the corresponding quarter of the previous year. This reflects positive top-line growth for the quarter.

Data Snapshot

  • Wockhardt Q2 revenue stood at ₹969 cr compared to ₹782 cr in the prior-year quarter.
  • Historical interim financial comparison shows prior-year quarterly revenue at ₹782 cr.

What's Changed

  • Q2 top-line revenue expanded to ₹969 cr from ₹782 cr in the corresponding prior-year period.
  • Year-on-year quarterly revenue grew by 23.91% (derived: ₹969 cr vs ₹782 cr).

Key Takeaways

  • Wockhardt registered Q2 revenue of ₹969 cr.
  • The figure compares with ₹782 cr reported in the corresponding quarter of the previous year.
  • Top-line traction reflects steady operational delivery across primary business units.

SAHI Perspective

The top-line increase to ₹969 cr highlights operational momentum for Wockhardt relative to ₹782 cr in the prior-year period. Sustained revenue delivery will remain key as market participants monitor detailed operational margins in forthcoming earnings filings.

Market Implications

Steady top-line growth indicates stable demand across Wockhardt's product categories, providing foundational revenue support for the quarter.

Trading Signals

Market Bias: Bullish

Q2 top-line revenue increased to ₹969 cr from ₹782 cr YoY, demonstrating a 23.91% growth rate.

Overweight: Pharmaceuticals

Trigger Factors:

  • Sustained quarterly revenue generation above ₹900 cr
  • Profitability and margin metrics in detailed financial statements

Time Horizon: Near-term (0-3 months)

Industry Context

Indian pharmaceutical manufacturers continue to emphasize top-line stability through product diversification and market reach across domestic and export segments.

Key Risks to Watch

  • Regulatory scrutiny in international markets
  • Input price inflation affecting manufacturing cost structures
  • Foreign exchange volatility

Recent Developments

No verified developments in this window

Closing Insight

Wockhardt's Q2 performance demonstrates strong top-line recovery, driven by revenue expansion to ₹969 cr from ₹782 cr YoY.

High Performance Trading with SAHI.

Disclaimer: This news section may include AI-generated or AI-assisted news, summaries, drafts, or insights. All content is subject to human review before publication. While we aim for accuracy, readers should independently verify information before relying on it.

Open Free Account

Frequently Asked Questions (FAQs)

All topics

Add Sahi as a Preferred Source on Google

Click the link, confirm the box next to sahi.com is checked — ignore any other results.